Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	0.25	33.49	4.93	2
Revenue Growth (YoY)	-	-99.25%	579.21%	146.30%	-
Gross Profit	-	0.25	33.49	4.93	2
Selling, General & Admin	20.27	17.21	13.91	20.78	12.86
Research & Development	69.54	50.33	50.25	43.98	42.41
Total Operating Expenses	89.81	67.53	64.16	64.76	55.27
Operating Income	-89.81	-67.28	-30.67	-59.83	-53.27
Interest Income	5.96	5.35	2.54	1.29	-
Other Non-Operating Income (Expense)	-0.01	-3.44	-0.51	-0.2	18.55
Total Non-Operating Income (Expense)	5.95	1.91	2.02	1.09	18.55
Pretax Income	-83.87	-65.37	-28.65	-58.74	-34.72
Provision for Income Taxes	-	-	-0.07	-0.05	-
Net Income	-83.87	-65.37	-28.72	-58.79	-34.72
Net Income to Common	-83.87	-65.37	-28.72	-58.79	-34.72
Shares Outstanding (Basic)	24	11	1	1	686
Shares Outstanding (Diluted)	24	11	1	1	686
Shares Change (YoY)	117.11%	1302.54%	4.70%	-99.89%	8.60%
EPS (Basic)	-3.43	-5.81	-35.78	76.67	-104.74
EPS (Diluted)	-3.43	-5.81	-35.78	76.67	-104.74
Free Cash Flow	-79.34	-55.67	-50.69	-57.13	-17.03
Free Cash Flow Per Share	-3.25	-4.94	-63.14	-74.51	-0.02
Gross Margin	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-26805.58%	-91.58%	-1213.32%	-2660.94%
Profit Margin	-	-26045.02%	-85.75%	-1192.21%	-1734.22%
FCF Margin	-	-22180.88%	-151.34%	-1158.55%	-850.55%
EBITDA	-87.21	-64.85	-28.41	-58.67	-53.02
EBITDA Margin	-	-25837.05%	-84.81%	-1189.84%	-2648.55%
EBIT	-89.81	-67.28	-30.67	-59.83	-53.27
EBIT Margin	-	-26805.58%	-91.58%	-1213.32%	-2660.94%
Effective Tax Rate	0.00%	0.00%	0.25%	0.09%	0.00%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q